Full Product Details
Author: Devanand Sarkar (Professor in the Department of Human and Molecular Genetics, and Associate Director of Education and Training at Massey Cancer Center, Virginia Commonwealth University (VCU)) ,
Paul B. Fisher (Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USA)
Publisher: Elsevier Science Publishing Co Inc
Imprint: Academic Press Inc
Volume: 120
Dimensions:
Width: 15.20cm
, Height: 1.80cm
, Length: 22.90cm
Weight: 0.530kg
ISBN: 9780124016767
ISBN 10: 0124016766
Pages: 264
Publication Date: 17 September 2013
Audience:
Professional and scholarly
,
Professional & Vocational
Format: Hardback
Publisher's Status: Active
Availability: Manufactured on demand
We will order this item for you from a manufactured on demand supplier.
Reviews
This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences. --AMERICAN SCIENTIST Excellent, highly informative, in-depth reviews...expertly written, up-to-date, and well-referenced. --JOURNAL OF MEDICINAL CHEMISTRY This is a series that has a long tradition of excellence in the field of cancer biology. --DOODY'S PUBLISHING REVIEW
Praise for the Serial This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences. --American Scientist Excellent, highly informative, in-depth reviews.expertly written, up-to-date, and well-referenced. --Journal of Medicinal Chemistry This is a series that has a long tradition of excellence in the field of cancer biology. --Doody's Publishing Reviews
"""This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences.""--AMERICAN SCIENTIST ""Excellent, highly informative, in-depth reviews...expertly written, up-to-date, and well-referenced.""--JOURNAL OF MEDICINAL CHEMISTRY ""This is a series that has a long tradition of excellence in the field of cancer biology.""--DOODY'S PUBLISHING REVIEW"
Author Information
Dr. Sarkar received his MBBS from Dhaka Medical College, Bangladesh and PhD from Nagoya University, Japan. After postdoctoral training in Columbia University, NY he joined Virginia Commonwealth University (VCU) as a faculty where he is now a Professor in the Department of Human and Molecular Genetics, and Associate Director of Education and Training at Massey Cancer Center. Dr. Sarkar’s research focuses on identifying novel regulators of hepatocellular carcinoma (HCC), especially obesity-induced HCC, and developing targeted gene- and immunotherapy based on the accrued knowledge. Dr. Sarkar has published more than 280 papers and his research is funded by NCI, NIDDK and DOD. Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
